208
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Edaravone administration in pivotal clinical Study 19

&
Pages 298-299 | Received 07 Jan 2019, Accepted 03 Feb 2019, Published online: 13 May 2019
 
View responses to this article:
Is edaravone harmful? (A placebo is not a control)
This article responds to:
Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin)

Acknowledgements

The authors thank p-value communications for editorial and medical writing assistance. p-value communications received funding from Mitsubishi Tanabe Pharma America, Inc., for their contributions.

Declaration of interest

Angela Genge is a consultant for Mitsubishi Tanabe Pharma America, AL-S Pharma, AveXis, Alexion, Alnylam Pharmaceuticals, Akcea Therapeutics, Biogen, AB Science, Roche, Novartis, Sanofi-Genzyme, UCB, and Brainstorm Cell Therapeutics. Benjamin Brooks is a consultant for Mitsubishi Tanabe Pharma America.

Additional information

Funding

This work was supported by Mitsubishi Tanabe Pharma America, Inc.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 478.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.